To ask the Secretary of State for Health and Social Care, what estimate he has made of the shortage of EpiPen 0.3mg Auto-Injectors in (a) Oxfordshire and (b) England; and what steps he is taking to address that shortage.
The United Kingdom supplier of EpiPen 0.3mg adrenaline auto-injectors, Mylan, has estimated that they are currently able to supply approximately 50% of their normal demand for this product. Within the UK there are two alternative 0.3mg adrenaline auto-injector devices and the manufacturers of these have been able to increase their supplies and support the market during this time. We therefore expect that patients will continue to be able to access 0.3mg adrenaline auto-injector devices if prescribed. The Department is working very closely with all the manufacturers of adrenaline auto-injectors, the Medicines and Healthcare products Regulatory Agency, NHS England, and others to try to resolve these issues and improve the situation as quickly as possible.